Animal Nutrition Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2023

PUNE, MAHARASHTRA, INDIA, February 22, 2018 /EINPresswire.com/ — Summary

WiseGuyReports.com adds “Animal Nutrition Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023” reports to its database.

This report provides in depth study of “Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Animal Nutrition Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization.

This report describes the development of the industry by upstream & downstream, industry overall and development, key companies, as well as type segment & market application and so on, and makes a scientific prediction for the development industry prospects on the basis of analysis, finally, analyzes opportunities for investment in the industry at the end of the report.

Global and Regional Animal Nutrition market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including

By Company
BASF
Cargill
Royal DSM
Nutreco
Evonik Industries
Novozymes
DuPont
Dow Chemical
Alltech
Kemin Industries
Archer-Daniels-Midland
Adisseo France

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/2641788-global-and-regional-animal-nutrition-market-research-report-2017

Market Segment as follows:
By Region
Asia-Pacific
North America
Europe
South America
Middle East & Africa

By Type
Amino Acids
Minerals
Vitamins
Lipids
Eubiotics
Enzymes
Carotenoids

By Application
Ruminants
Poultry
Aquaculture
Swine
Equine
Pets
Others

Table of Contents

1 Market Overview
1.1 Market Segment Overview
1.1.1 Product Definition
1.1.2 Market by Type
1.1.2.1 Amino Acids
1.1.2.2 Minerals
1.1.2.3 Vitamins
1.1.2.4 Lipids
1.1.2.5 Eubiotics
1.1.2.6 Enzymes
1.1.2.7 Carotenoids
1.1.3 Market by Application
1.1.3.1 Ruminants
1.1.3.2 Poultry
1.1.3.3 Aquaculture
1.1.3.4 Swine
1.1.3.5 Equine
1.1.3.6 Pets
1.1.3.7 Others
1.2 Global and Regional Market Size
1.2.1 Global Overview
1.2.2 Market by Region
1.2.2.1 Asia-Pacific
1.2.2.2 North America
1.2.2.3 Europe
1.2.2.4 South America
1.2.2.5 Middle East & Africa

…..

6 Key Manufacturers
6.1 BASF
6.1.2 Company Information
6.1.2 Product Specifications
6.1.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
6.2 Cargill
6.2.1 Company Information
6.2.2 Product Specifications
6.2.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
6.3 Royal DSM
6.3.1 Company Information
6.3.2 Product Specifications
6.3.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
6.4 Nutreco
6.4.1 Company Information
6.4.2 Product Specifications
6.4.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
6.5 Evonik Industries
6.5.1 Company Information
6.5.2 Product Specifications
6.5.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
6.6 Novozymes
6.6.1 Company Information
6.6.2 Product Specifications
6.6.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
6.7 DuPont
6.7.1 Company Information
6.7.2 Product Specifications
6.7.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
6.8 Dow Chemical
6.8.1 Company Information
6.8.2 Product Specifications
6.8.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
6.9 Alltech
6.9.1 Company Information
6.9.2 Product Specifications
6.9.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
6.10 Kemin Industries
6.10.1 Company Information
6.10.2 Product Specifications
6.10.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
6.11 Archer-Daniels-Midland
6.12 Adisseo France

Continued….

Contact Us: sales@wiseguyreports.com

Ph: +1-646-845-9349 (US) ; Ph: +44 208 133 9349 (UK)

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Vaginal Pessary Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2023

PUNE, MAHARASHTRA, INDIA, February 22, 2018 /EINPresswire.com/ — Summary

WiseGuyReports.com adds “Vaginal Pessary Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023” reports to its database.

This report provides in depth study of “Vaginal Pessary Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Vaginal Pessary Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization.

a vaginal pessary is a removable device placed into the vagina. It is designed to support areas of pelvic organ prolapse.Vaginal pessaries can be broadly divided into two types: support and space-filling pessaries
This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions.

Global Vaginal Pessary market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including

By Company
CooperSurgical
MedGyn
Personal Medical Corp
Integra LifeSciences
Panpac Medical
Medesign
Smiths Medical
Thomas Medical
Kangge Medical
Dr. Arabin

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/2741397-2015-2023-world-vaginal-pessary-market-research-report-by-product

Market Segment as follows:
By Region / Countries
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain etc)
South America (Brazil, Argentina etc)
Middle East & Africa (Saudi Arabia, South Africa etc)

By Type
Ring Pessary
Shelf Pessary

By End-User / Application
Mild Pelvic Organ Prolapse
Stress Urinary Incontinence
Severe Pelvic Organ Prolapse

Table of Contents

1 Market Definition
1.1 Market Segment Overview
1.2 by Type
1.3 by End-Use / Application

2 Global Market by Vendors
2.1 Market Share
2.2 Vendor Profile
2.3 Dynamic of Vendors

3 Global Market by Type
3.1 Market Share
3.2 Introduction of End-Use by Different Products

4 Global Market by End-Use / Application
4.1 Market Share
4.2 Overview of Consumption Characteristics
4.2.1 Preference Driven
4.2.2 Substitutability
4.2.3 Influence by Strategy
4.2.4 Professional Needs

5 Global Market by Regions
5.1 Market Share
5.2 Regional Market Growth
5.2.1 North America
5.2.2 Europe
5.2.3 Asia-Pacific
5.2.4 South America
5.2.5 Middle East & Africa

…..

12 Key Manufacturers
12.1 CooperSurgical
12.1.2 Company Overview
12.1.2 Product and End-User / Application
12.1.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
12.2 MedGyn
12.2.1 Company Overview
12.2.2 Product and End-User / Application
12.2.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
12.3 Personal Medical Corp
12.3.1 Company Overview
12.3.2 Product and End-User / Application
12.3.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
12.4 Integra LifeSciences
12.4.1 Company Overview
12.4.2 Product and End-User / Application
12.4.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
12.5 Panpac Medical
12.5.1 Company Overview
12.5.2 Product and End-User / Application
12.5.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
12.6 Medesign
12.12.1 Company Overview
12.12.2 Product and End-User / Application
12.12.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
12.7 Smiths Medical
12.7.1 Company Overview
12.7.2 Product and End-User / Application
12.7.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
12.8 Thomas Medical
12.8.1 Company Overview
12.8.2 Product and End-User / Application
12.8.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
12.9 Kangge Medical
12.9.1 Company Overview
12.9.2 Product and End-User / Application
12.9.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
12.10 Dr. Arabin
12.10.1 Company Overview
12.10.2 Product and End-User / Application
12.10.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)

Continued….

Contact Us: sales@wiseguyreports.com

Ph: +1-646-845-9349 (US) ; Ph: +44 208 133 9349 (UK)

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Sexual Enhancement Supplements Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2023

PUNE, MAHARASHTRA, INDIA, February 22, 2018 /EINPresswire.com/ — Summary

WiseGuyReports.com adds “Sexual Enhancement Supplements Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023” reports to its database.

This report provides in depth study of “Sexual Enhancement Supplements Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Sexual Enhancement Supplements Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization.

Sexual Enhancement Supplements work by increasing the amount of blood flow the genital region receives and the volume of blood that it can retain.

Global Sexual Enhancement Supplements market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including

By Company
Innovus Pharmaceuticals
Leading Edge Health
Direct Digital
SizeGenix
Vimax
Xanogen
Vydox
TEK Naturals

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/2812307-global-sexual-enhancement-supplements-market-research-report-2018

Market Segment as follows:
By Region
Asia-Pacific (Segment by Company, Type and Application)
North America (Segment by Company, Type and Application)
Europe (Segment by Company, Type and Application)
South America (Segment by Company, Type and Application)
Middle East & Africa (Segment by Company, Type and Application)

By Type
Male Sexual Enhancement Supplements
Female Sexual Enhancement Supplements

By Application
Physical Stores
Online Stores

Table of Contents

1 Market Overview
1.1 Market Segment Overview
1.1.1 Product Definition
1.1.2 Market by Type
1.1.2.1 Male Sexual Enhancement Supplements
1.1.2.2 Female Sexual Enhancement Supplements
1.1.3 Market by Application
1.1.3.1 Physical Stores
1.1.3.2 Online Stores
1.2 Global and Regional Market Size
1.2.1 Global Overview
1.2.2 Market by Region
1.2.2.1 Asia-Pacific
1.2.2.2 North America
1.2.2.3 Europe
1.2.2.4 South America
1.2.2.5 Middle East & Africa

…..

6 Key Manufacturers
6.1 Innovus Pharmaceuticals
6.1.2 Company Information
6.1.2 Product Specifications
6.1.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
6.2 Leading Edge Health
6.2.1 Company Information
6.2.2 Product Specifications
6.2.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
6.3 Direct Digital
6.3.1 Company Information
6.3.2 Product Specifications
6.3.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
6.4 SizeGenix
6.4.1 Company Information
6.4.2 Product Specifications
6.4.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
6.5 Vimax
6.5.1 Company Information
6.5.2 Product Specifications
6.5.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
6.6 Xanogen
6.6.1 Company Information
6.6.2 Product Specifications
6.6.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
6.7 Vydox
6.7.1 Company Information
6.7.2 Product Specifications
6.7.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
6.8 TEK Naturals
6.8.1 Company Information
6.8.2 Product Specifications
6.8.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)

Continued….

Contact Us: sales@wiseguyreports.com

Ph: +1-646-845-9349 (US) ; Ph: +44 208 133 9349 (UK)

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Myocarditis Therapeutic Pipeline Market Review, H1 2018

Myocarditis Pharmaceutical and Healthcare Pipeline Review H1

PUNE , INDIA, February 22, 2018 /EINPresswire.com/ — Summary
Myocarditis is inflammation of the heart muscle. Myocarditis is an uncommon disorder that is usually caused by viral, bacterial, or fungal infections that reach the heart. Symptoms include chest pain, rapid or abnormal heartbeat, shortness of breath, at rest or during physical activity, fluid retention with swelling of legs, ankles and feet and fatigue. Treatment includes antibiotics, anti-inflammatory medicines to reduce swelling and diuretics to remove excess water from the body.

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Myocarditis – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Myocarditis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2989078-myocarditis-pipeline-review-h1-2018

The Myocarditis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocarditis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III and Preclinical stages are 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Myocarditis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Myocarditis (Cardiovascular).
– The pipeline guide reviews pipeline therapeutics for Myocarditis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Myocarditis (Cardiovascular) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Myocarditis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Myocarditis (Cardiovascular)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Myocarditis (Cardiovascular).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Myocarditis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
List of Tables
List of Figures
Introduction
Myocarditis – Overview
Myocarditis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Myocarditis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myocarditis – Companies Involved in Therapeutics Development
CEL-SCI Corp
Evotec AG
Swedish Orphan Biovitrum AB
Myocarditis – Drug Profiles
anakinra – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEL-1000 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2989078-myocarditis-pipeline-review-h1-2018

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

US Ambulatory (ECG) Market Analysis 2018 (By Segment, Key Players and Applications) and Forecasts To 2022

US Ambulatory (ECG) Market 2018 Analysis, Opportunities and Forecast to 2022

PUNE , INDIA, February 22, 2018 /EINPresswire.com/ — The ambulatory ECG records the electrical activity of heart while walking (ambulatory) and doing normal activities. In contrast to the usual 12 lead ECG, where the heart’s electrical signals are captured for only a few seconds, the continuous ambulatory ECG monitor can record such signals over a prolonged period at the patient’s own home or work environment.

Ambulatory ECG monitoring, which can be performed using a variety of techniques for as short as 24 to 48 hours and for as long as months to years, offers the opportunity to review cardiac ECG data during normal routine activity, including any physical and psychological stresses. Ambulatory ECG monitoring for longer periods (when compared with standard ECG for a 10-second time period) is more sensitive for detecting spontaneous, often highly variable cardiac arrhythmias or conduction abnormalities. Current ambulatory ECG monitoring technologies include traditional holter, event monitors, mobile cardiac outpatient telemetry (MCOT) and implantable loop recorders.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/3003076-us-ambulatory-electrocardiography-ecg-market-industry-analysis-outlook-2018-2022

The US ambulatory ECG market is set to experience favorable growth driven by factors such rising ageing population, increasing health care expenditure, accelerating economic growth, growing burden of atrial fibrillation and rise in prevalence of cardiovascular disorders. The major trends observed in this market include technological advancements, increased demand for home based monitoring systems product innovation- PocketECG. However, the growth of this budding is constrained by challenges such as high competition, stringent regulations and high barriers to entry.

The report “The US Ambulatory ECG Market: Industry Analysis & Outlook (2018-2022)” analyses the development of this market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: BioTelemetry, Inc., Koninklijke Philips N.V, iRhythm Technologies Inc. and Medtronic Plc. are being profiled along with their key financials and strategies for growth.

Table of Content: Key Points
1. Overview
2. The US Ambulatory ECG Market
3. Market Dynamics
4. Competitive Landscape
5. Company Profiles
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/3003076-us-ambulatory-electrocardiography-ecg-market-industry-analysis-outlook-2018-2022

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Hexamethylene Diisocyanate Industry: 2018 Global Market Size, Share, Trends, Key Manufacturers and 2023 Demand Forecast

Hexamethylene Diisocyanate Market Research Report 2018

2018-2023 World Hexamethylene Diisocyanate Market Research Report

Latest research report on “Global Hexamethylene Diisocyanate Market 2018 Research Report ” now available at a high quality database of OrianResearch.com

PUNE, MAHARASHTRA, INDIIA, February 22, 2018 /EINPresswire.com/ — The Global Hexamethylene Diisocyanate Market Report 2018 is a professional and in-depth study on the current state of the Hexamethylene Diisocyanate industry. The report provides a basic overview of the market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries.

The Hexamethylene Diisocyanate industry analysis is provided for the international markets including product types and end industries in global and major regions.

Get Sample Copy of this Report at – https://www.orianresearch.com/request-sample/459912 .

The report provides a basic critique of the industry including objective research, operations and industry upstream and downstream chain structure. The Hexamethylene Diisocyanate Market analysis is provided for the international market including development antiquity, cutthroat landscape scrutiny and key regions evolution stature.

Complete report on Hexamethylene Diisocyanate Market report spread across 118 pages, profiling 06 companies and supported with tables and figures available. Enquire more @ https://www.orianresearch.com/enquiry-before-buying/459912 .

Analysis of Hexamethylene Diisocyanate Market Key Companies –
• Vencorex
• Bayer
• BASF SE
• Asahi Kasei Corporation
• Tosoh
• WANHUA

This report focuses on Capacity, Sales Revenue, Volume, Price, Cost and Margin, as well as the each type price of key manufacturers, through interviewing key manufacturers.

On basis of segments by manufacturers, this report focuses on the sales, price of each type, average price of Hexamethylene Diisocyanate, revenue and market share, for key manufacturers.

Market Segment By Region / Countries this report covers:-
• North America (U.S., Canada, Mexico)
• Europe (Germany, U.K., France, Italy, Russia, Spain etc)
• South America (Brazil, Argentina etc)
• Middle East & Africa (Saudi Arabia, South Africa etc)

Market Segment By Type this report covers:-
• Purity 99.9%
• Purity 99.5%
• Others

Market Segment By End-User / Application this report covers:-
• Paints
• Adhesive
• Others

The report spotlights on global major leading industry participants with information such as company portraits, product snaps and specification, scope, production, price, revenue and contact information. Upstream raw materials, equipment and downstream consumers analysis is also carried out. What’s further, the worldwide Hexamethylene Diisocyanate industry development trends and marketing carriers are analysed.

With the list of tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Get Direct Copy of this Report @ https://www.orianresearch.com/checkout/459912 .

Major Points Covered in Table of Contents:
1 Market Definition
2 Global Market by Vendors
3 Global Market by Type
4 Global Market by End-Use / Application
5 Global Market by Regions
6 North America Market
7 Europe Market
8 Asia-Pacific Market
9 South America Market
10 Middle East & Africa Market
11 Market Forecast
12 Key Manufacturers
Research Conclusion
Data Source

Ruwin Mendez
OrianResearch Consultants
+1 832-380-8827
email us here


Source: EIN Presswire

Northern Maine Medical Center Named 2018 100 SafeCare hospitals®

Recognized for low infections, low readmissions, low complications by The SafeCare Group®

Congratulations to Northern Maine Medical Center on achieving 100 SafeCare Hospitals”

— Yisrael Safeek, MD, MBA, CEO, The SafeCare Group

LEXINGTON, KY, USA, February 22, 2018 /EINPresswire.com/ — Northern Maine Medical Center was recognized as a 2018 100 SafeCare Hospitals® by The SafeCare Group® for low infections, low readmissions, low complications.

100 SafeCare Hospitals® represent the nation’s top performing hospitals in evidence-based metrics of Medical and Surgical Infections, 30-Day Mortality rates, Complications rates for Medical and Surgical Care, Patient Satisfaction, 30-Day Medical and Surgical Readmissions, and overall value.

100 SafeCare Hospitals have achieved an exemplary level of performance in the comprehensive, evidence-based metrics of the Centers of Medicare and Medicaid (CMS) value-based program (HVBP), readmissions reduction program (HRRP), and acquired complications reduction program (HACRP). Hospitals that perform poorly on these quality, safety, and efficiency metrics receive a financial penalty from the government. Only about two percent of US hospitals earn the prestigious 100 SafeCare Hospitals® distinction, and the top 50 hospitals represent the top one percent performance in the evidence-based metrics of HVBP, HACRP, and HRRP.

“While all US hospitals achieving improvements deserve recognition,” says Dr. Yisrael Safeek, MD, MBA, Chairman and CEO of The SafeCare Group®, “those achieving 100 SafeCare Hospitals distinction are leading the way. Congratulations to Northern Maine Medical Center on achieving within the top 50 of 100 SafeCare Hospitals with low infections, low complications, and low readmissions.”

About 100 SafeCare Hospitals®
The SafeCare Group® published the first 100 SafeCare Hospitals® listing in 2013 with the mission of “Recognizing Healthcare Excellence”. 100 SafeCare Hospitals recognize hospitals that excel in evidence-based metrics of Medical and Surgical Infections, 30-Day Mortality rates, Complications rates for Medical and Surgical Care, Patient Satisfaction, 30-Day Medical and Surgical Readmissions, and value of care. The top 50 hospitals represent the top 1% performance in the evidence-based metrics of HVBP, HACRP, and HRRP, and only about 2% percent of US hospitals earn the prestigious 100 SafeCare Hospitals® distinction. Hospitals that performed poorly on these evidence-based metrics receive a financial penalty from the Centers of Medicare and Medicaid Services. The SafeCare Group believes that the 100 SafeCare Hospitals listings would incentivize hospital leadership to improve care and reduce unnecessary errors that harm patients.

About the SafeCare Group
The SafeCare Group was founded in 2010 and is a privately held company with the motto Softwaring Healthcare Excellence®. The SafeCare Group software solutions enable hospitals to take advantage of disruptive healthcare technologies that optimize hospital reimbursement and accreditation. Since 2012, SafeCare Analytics® have been helping hospitals excel with physician privileging software for Joint Commission OPPE, and hospital software for better readmissions, cost, complications and infections. Since 2013, 100 SafeCare Hospitals® listings have been Recognizing Healthcare Excellence® of 100 US hospitals that excelled with low infections, readmissions, and complications. Since 2015, SafeCare® magazine has been delivering information on the people, ideas and novel technologies affecting access, cost, and quality of healthcare across the globe. For more information about The SafeCare Group, visit www.safecaregroup.com.

Sarju Bharucha, JD
SafeCare Magazine
800-700-9481
email us here

Comparative Performance of 100 SafeCare Hospitals®


Source: EIN Presswire

Neuromyelitis Optica – Disease Assessment and Therapeutics Analysis Forecasts to 2024

Neuromyelitis Optica

PUNE, MAHARASHTRA, INDIA, February 22, 2018 /EINPresswire.com/ — WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Neuromyelitis Optica – Pipeline Review, H2 2017”

Neuromyelitis Optica 

Overview

Neuromyelitis Optica refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/2258239-neuromyelitis-optica-devic-s-syndrome-pipeline-review-h2-2017

Top Companies mentioned

2-BBB Medicines BV

Alexion Pharmaceuticals Inc

HanAll Biopharma Co Ltd

LFB SA

MedImmune LLC

Opexa Therapeutics Inc

Shire Plc

Vicore Pharma AB

Neuromyelitis Optica Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Neuromyelitis Optica   – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Neuromyelitis Optica  , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuromyelitis Optica (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuromyelitis Optica and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 13, 4, 17 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Neuromyelitis Optica pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Neuromyelitis Optica – Competitive Analysis

Key players are making innovative developments in Neuromyelitis Optica industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica.

The pipeline guide reviews pipeline therapeutics for Neuromyelitis Optica by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Neuromyelitis Optica therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Neuromyelitis Optica therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 

The pipeline guide reviews latest news related to pipeline therapeutics for Neuromyelitis Optica.

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2258239-neuromyelitis-optica-devic-s-syndrome-pipeline-review-h2-2017

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Premature Labor (Tocolysis) Pipeline Review, H1 2018- Identify Key Business Opportunities

Premature Labor (Tocolysis) Market

PUNE, MAHARASHTRA, INDIA, February 22, 2018 /EINPresswire.com/ —

WiseGuyReports published new report, titled “Premature Labor (Tocolysis) – Pipeline Review, H1”

SUMMARY

Pharmaceutical and Healthcare disease pipeline guide Premature Labor (Tocolysis) – Pipeline Review, H1 2018, provides an overview of the Premature Labor (Tocolysis) (Women's Health) pipeline landscape.
Preterm labor or premature labor is defined as labor that begins before completion of 36 weeks of pregnancy. Symptoms include sensation of pelvic or lower abdominal pressure, mild abdominal cramps, diarrhea, vaginal spotting or bleeding and constant low, dull backache. Treatment includes corticosteroids and tocolytics.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/3010398-premature-labor-tocolysis-pipeline-review-h1-2018

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Premature Labor (Tocolysis) – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Premature Labor (Tocolysis) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Premature Labor (Tocolysis) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Premature Labor (Tocolysis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Premature Labor (Tocolysis) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Premature Labor (Tocolysis) (Women's Health).
– The pipeline guide reviews pipeline therapeutics for Premature Labor (Tocolysis) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Premature Labor (Tocolysis) (Women's Health) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Premature Labor (Tocolysis) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Premature Labor (Tocolysis) (Women's Health)

Key points

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Premature Labor (Tocolysis) (Women's Health).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Premature Labor (Tocolysis) (Women's Health) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

..CONTINUED

About US

Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

For accessing accurate and deep understanding and to gain latest insights and key developments in the area of your interest, we also have a list of conferences in which you will be interested in, for more information, cordially check

https://www.wiseguyreports.com/conferences

For updating knowledge or for thoroughly understanding various terminologies, we also have vast list of seminars for your reference, for more information cordially check

https://www.wiseguyreports.com/seminars

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Dyskinesia Market Size Share And Key Players – Pipeline Review, H2 2017

Dyskinesia 

PUNE, MAHARASHTRA, INDIA, February 22, 2018 /EINPresswire.com/ — WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Dyskinesia – Pipeline Review, H2 2017”

Dyskinesia 

Overview

Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/2258240-dyskinesia-pipeline-review-h2-2017

Top Companies mentioned

Avanir Pharmaceuticals Inc

Bionomics Ltd

Catalyst Biosciences Inc

Neurolixis Inc

Osmotica Pharmaceutical Corp

Phenomenome Discoveries Inc

Sage Therapeutics Inc

Dyskinesia Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Dyskinesia   – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Dyskinesia  , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 13, 4, 17 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Dyskinesia pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Dyskinesia – Competitive Analysis

Key players are making innovative developments in Dyskinesia industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Dyskinesia.

The pipeline guide reviews pipeline therapeutics for Dyskinesia by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Dyskinesia therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Dyskinesia therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 

The pipeline guide reviews latest news related to pipeline therapeutics for Dyskinesia.

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2258240-dyskinesia-pipeline-review-h2-2017

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

NORAH TRENT
Wise Guy Reports
+91 841 198 5042
email us here


Source: EIN Presswire